T1	Participants 686 972	Eligible subjects in a multicenter, double-masked, randomized, parallel-group, placebo-controlled, natural exposure clinical trial were randomly assigned to either BBOS 1.5% or placebo eyedrops on a 1:1 basis and instilled 1 drop of the test agent into both eyes twice daily for 2 weeks
T2	Participants 1184 1251	Subject-reported adverse events (AEs) were also recorded for safety
